USP30, a deubiquitinating enzyme
family, forfeits the ubiquitination
of E3 ligase and Parkin on the surface of mitochondria. Inhibition
of USP30 results in mitophagy and cellular clearance. Herein, by understanding
structural requirements, we discovered potential USP30 inhibitors
from an imidazole series of ligands via a validated ubiquitin-rhodamine-110
fluorometric assay. A novel catalytic use of the Zn(l-proline)2 complex for the synthesis of tetrasubstituted imidazoles
was identified. Among all compounds investigated, 3g and 3f inhibited USP30 at IC50 of 5.12 and 8.43 μM,
respectively. The binding mode of compounds at the USP30 binding site
was understood by a docking study and interactions with the key amino
acids were identified. Compound 3g proved its neuroprotective
efficacy by inhibiting apoptosis on SH-SY5Y neuroblastoma cells against
dynorphin A (10 μM) treatment. Hence, the present study provides
a new protocol to design and develop ligands against USP30, thereby
offering a therapeutic strategy under conditions like kidney damage
and neurodegenerative disorders including Parkinson’s disease.